Why Summit Therapeutics Stock Soared 8% Higher Today
This could be worth up to $15 billion in total, according to a media report.
10 stocks we like better than Summit Therapeutics ›
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal. That rise bettered the S&P 500's (SNPINDEX: ^GSPC) 0.8% increase by several orders of magnitude.
The media outlet in question was Bloomberg, which that morning published an article asserting that AstraZeneca is in talks with Summit about a partnership between the two companies.
According to unnamed "people familiar with the matter," the piece stated that such a partnership would center on the investigational lung cancer treatment ivonescimab. The drug, which Summit licenses from Chinese peer Akeso, has recently attracted much attention from the healthcare community and investors alike. This was due to its impressive performance in a late-stage clinical trial.
Bloomberg's sources said that the terms of a potential deal were still being hashed out. They might include an up-front payment of several billion dollars, and several milestone payments over time (this kind of structure is common in pharmaceutical industry licensing/partnership arrangements). All told, a deal between the two companies could pay out as much as $15 billion.
Both Summit and AstraZeneca declined comment on the Bloomberg article.
When a drug development program attracts $15 billion worth of interest from a major industry player with deep pockets, it's almost indisputably a win. If the Bloomberg report is accurate and a deal is indeed in the works (and is ultimately agreed upon), it would open a great, powerful, and quick road to success for Summit. It's little wonder investors were so happy about the possibility.
Before you buy stock in Summit Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
Why Summit Therapeutics Stock Soared 8% Higher Today was originally published by The Motley Fool
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Century Aluminum (CENX) Plans New US Smelter After Higher Aluminum Tariffs
Century Aluminum Company (NASDAQ:CENX) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On June 2, Century Aluminum Company (NASDAQ:CENX) praised President Trump's decision to raise tariffs on imported aluminum from 25% to 50%. This move aims to encourage investment and job growth in the US aluminum industry and support the nation's domestic production of critical metals. A warehouse of aluminum ingots, neatly lined up ready to be shipped. With this support, Century Aluminum Company (NASDAQ:CENX) has announced plans to build the first new aluminum smelter in the US in 50 years. The company also intends to double its domestic production. Century Aluminum Company (NASDAQ:CENX) is the largest producer of primary aluminum in the US. The company is an integrated producer of bauxite, alumina, and primary aluminum products. It also has production facilities in Iceland, the Netherlands, and Jamaica. While we acknowledge the potential of CENX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11 minutes ago
- Yahoo
Scotiabank Raises Comcast (CMCSA) Price Target, Maintains Sector Perform Rating
Comcast Corporation (NASDAQ:CMCSA) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Scotiabank has nudged its price target on Comcast Corporation (NASDAQ:CMCSA) to $45 from $44.50, maintaining a rating on the stock. The adjustment reflects the bank's cautious optimism toward the broader Telecom, Media, and Technology (TMT) space as macroeconomic pressures intensify. A couple watching their favorite show on TV, enjoying the entertainment network service. In a note to clients, Scotiabank analysts described the TMT sector as a 'great place to hide' amid mounting global uncertainties, including slowing economic momentum and the impact of escalating tariff disputes. The firm sees companies like Comcast as relatively well-positioned to weather volatility, offering stability in a shifting landscape. While financial performance across the sector is expected to hold steady, Scotiabank flagged potential softness in key subscriber metrics. The bank pointed to slowing population growth, largely attributed to reduced immigration, as a factor that may weigh on new customer acquisition, particularly in broadband and wireless segments. Still, the firm sees Comcast's diversified portfolio, which spans broadband, content, and theme parks, as a buffer against near-term pressures. The modest target increase reflects both confidence in Comcast's earnings potential and caution over demographic headwinds. While we acknowledge the potential of CMCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11 minutes ago
- Yahoo
AppLovin (APP) Reaffirmed as Top Pick by Citi Ahead of Q2 Earnings
Applovin Corporation (NASDAQ:APP) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Applovin Corporation (NASDAQ:APP) shares jumped on Monday after Citi reiterated the stock as a top pick heading into the company's second-quarter earnings report, scheduled for August 6. The firm reaffirmed its Buy rating and maintained a $600 price target, citing confidence in AppLovin's performance and outlook. In a note to clients, Citi said it expects second-quarter results to come in at the high end of management's guidance ranges. The firm also highlighted strength in AppLovin's software platform and monetization strategy as key drivers of momentum heading into the second half of 2025 and into 2026. Citi's note emphasized that tailwinds from AI-driven ad targeting and growing demand for mobile app optimization tools continue to support revenue acceleration. With solid execution and rising visibility into long-term growth, Applovin Corporation (NASDAQ:APP) remains well-positioned in a competitive digital ecosystem. The company's upcoming earnings report will be closely watched for further signs of momentum, as investors look for confirmation of Citi's bullish stance and any upward revisions to guidance. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.